Abstract-Most guidelines have recommended lower home blood pressure (BP) threshold when clinic BP threshold of 140/90 mm Hg is used for diagnosis of hypertension. However, home BP thresholds to define hypertension have never been determined in the general population in the United States. We identified home BP thresholds for stage 1 (BP ≥130/80 mm Hg) hypertension using a regression-based approach in the DHS (Dallas Heart Study; n=5768) and the NCMH study (North Carolina Masked Hypertension; n=420). Home BP thresholds were also assessed using outcome-derived approach based on the composite of all-cause mortality or cardiovascular events in the DHS cohort. For this approach, BP thresholds were identified only for systolic BP because diastolic BP was not associated with the outcome. Among untreated participants, the regression-derived thresholds for home BP corresponding to clinic BP for stage 1 hypertension were 129/80 mm Hg in blacks, 130/80 mm Hg in whites, and 126/78 mm Hg in Hispanics, respectively. The results are similar in the North Carolina cohort. The 11-year composite cardiovascular and mortality events corresponding to clinic systolic BP >130 mm Hg were higher in blacks than in whites and Hispanics (13.3% versus 5.98% versus 5.52%, respectively). Using a race/ethnicity-specific composite outcome in the untreated DHS participants, the outcome-derived home systolic BP thresholds corresponding to stage 1 hypertension were 130 mm Hg in blacks, 129 mm Hg in whites, and 131 mm Hg in Hispanics, respectively. Our data based on both regression-derived and outcome approach support home BP threshold of 130/80 mm Hg for diagnosis of hypertension in blacks, whites, and Hispanics. (Hypertension.
S everal recent hypertension guidelines have placed a major emphasis on out-of-office blood pressure (BP) measurements to confirm the diagnosis of hypertension and assess hypertension control. [1] [2] [3] The new recommendation reflects strong evidence for the superiority of out-of-office BP over clinic BP in predicting target organ damage and cardiovascular mortality. [4] [5] [6] The new American College of Cardiology (ACC)/American Heart Association (AHA) guideline has also proposed different BP thresholds for home and office BP for initiation or titration of antihypertensive drug treatment. 1 For example, the clinic BP cutoff of 140/90 and 160/100 mm Hg is proposed to be equivalent to lower home BP threshold of 135/85 and 145/90 mm Hg, respectively. The home BP cutoff level for stage 1 hypertension is proposed to be the same as the clinic BP threshold of 130/80 mm Hg.
These home BP thresholds are derived from epidemiological studies comparing home and clinic BP among Asian and European individuals. 7 Although BP measurement in the doctors' office generally yields higher values than measurement outside the clinics (ie, a white coat phenomenon), recent studies conducted in the United States have identified an opposite phenotype, in which out-of-office BP is higher than clinic BP. This phenomenon, known as masked hypertension, is particularly common among blacks. 8 For example, in the JHS (Jackson Heart Study), the prevalence of masked hypertension was reported to be between 25% and 34% among blacks. 9, 10 Similarly, other studies conducted in more ethnically diverse populations in the Dallas county 11 and New York, NY 12 showed a prevalence of masked hypertension between 20% and 30% of participants. Despite evidence to suggest that home BP may be higher than office BP, at least in certain US populations, previous studies have not determined home BP thresholds that correspond with office BP cutoffs for each stage of hypertension in the general US adults.
Accordingly, we analyzed data from the DHS (Dallas Heart Study) and the NCMH study (North Carolina Masked Hypertension). In these 2 cohorts, BP was measured both at home and in the clinic using a standardized protocol and validated oscillometric BP monitors in all participants. We identified home BP thresholds using both regression approach and outcome approach that yield similar probability of cardiovascular disease events as the clinic BP thresholds from the DHS cohort, which has adjudicated cardiovascular outcome data.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Study Population

Dallas Heart Study
The DHS is a multiethnic probability-based population sample of Dallas County residents aged 18 to 65 years, established in 2000, as described previously. 11, 13, 14 The first DHS data collection (DHS-1) was designed to oversample blacks, including 54% blacks and 49% women. All participants in the DHS provided written informed consent, and the University of Texas Southwestern Medical Center Institutional Review Board approved the study. During the first in-home visit (n=6101), surveyors collected medical history, BP, and anthropometric measurements between years 2000 and 2002. During the in-home visit, 5 BP measurements were taken in the seated position using an automatic oscillometric device (Welch Allyn Vital Signs, Skaneateles Falls, NY) after resting quietly for 5 minutes. Treatment with antihypertensive medications and the type of antihypertensive treatment by drug, dose, and frequency was verified by the surveyors. Of the initial 6101 participants, 3271 subjects between the age of 30 and 65 years had BP measurements during 2 separate home visits. Total of 10 home BP measurements were obtained in this group of subjects (5 measurements in visit 1 and 5 measurements in visit 2). Among these subjects, 3027 subjects completed a third study visit at UT Southwestern Medical Center where 5 clinic BP measurements were obtained in the same fashion as the in-home visit using the same model of oscillometric device (Welch Allyn Vital Signs). The regression-derived analyses were applied to the 2934 subjects who had no missing values of both home and clinic BP readings. Nonfatal end point surveillance was only collected for the cohort entering visit 2, who reported no history of cardiovascular disease at baseline (n=3132). Among this group, 2503 subjects had complete follow-up for the outcome-derived analyses.
NCMH Study
The NCMH study is a community-based study that enrolled 420 adults from primary care clinics in North Carolina. 15 The NCMH study was designed to examine the short-term reproducibility of BP phenotypes defined using ambulatory and home BP monitoring during 2 separate testing sessions. Recruitment was restricted to adults who were ≥30 years of age, had a screening clinic-measured systolic BP (SBP)/ diastolic BP (DBP) between 120 and 149/80 and 95 mm Hg, had a dedicated primary care physician, and were not taking antihypertensive medication. Exclusion criteria included participants with clinicmeasured BP ≥160/100 or <110/70 mm Hg, pregnancy, dementia, any condition that would preclude wearing an ambulatory BP monitor, and persistent atrial fibrillation or other arrhythmia. At each study visit, trained research staff measured nondominant arm brachial artery BP 3× at ≥1-minute intervals after the participant had been sitting in a quiet room for 5 minutes, using a validated clinic oscillometric device (Welch Allyn Vital Signs). 16 At the second study visit, participants were instructed on how to perform home BP measurements using an Omron 705CP HBPM. 17 Between the second and third visits, and between the fourth and fifth (exit) visits, 3 home BP readings were taken at 1-minute intervals with patients in a seated position after a 5-minute rest in the morning and evening for 5 consecutive days. Thus, there were total of 60 home BP measurements per each subject (30 between the second and third visits and 30 between the fourth and fifth visits).
Variable Definitions
Race/ethnicity was self-reported. We considered the mean of all available home BP measurements. The average of all 5 clinic BP from visit 3 in the DHS and 6 clinic BP in the NCMH cohort (3 readings from visit 3 and 3 from visit 5) which are closer to the time of home BP monitoring) was used as the clinic BP in the analysis.
Outcome Measures
Mortality data were queried from the National Death Index through December 2012. Cardiovascular death was defined by International Classification of Diseases, Tenth Revision, codes I00-I99. Two overlapping approaches were used to capture nonfatal cardiovascular disease events occurring after enrollment as described previously. 18 First, a detailed health survey on interval cardiovascular events was administered annually to study participants. Second, quarterly tracking was performed for hospital admissions using the Dallas-Fort Worth Hospital Council Data Initiative Database-a consortium of all acute-care hospitals in Dallas County. Primary clinical source documents were reviewed for all suspected nonfatal cardiovascular events and were independently adjudicated by an end point committee blinded to all study data. Adjudicated cardiovascular events included unstable angina, myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention, stroke, transient ischemic attack, cerebrovascular revascularization, peripheral artery revascularization, hospitalization for atrial fibrillation or heart failure, and all-cause mortality. Follow-up data for both fatal and nonfatal events were complete through December 31, 2012.
Statistical Analysis
All analyses were conducted using SAS, version 9.4 (SAS Institute, Cary, NC). We used 2 approaches to identify thresholds for home BP: a regression-derived approach and an outcome-derived approach. 7, [19] [20] [21] To enable evaluation of BP thresholds for initiation of antihypertensive drug in untreated participants, all of these analyses were stratified by antihypertensive drug use. Because prevalence of masked hypertension in blacks was suggested to be higher than the prevalence in other ethnicities based on 24-hour ambulatory BP monitoring studies, 9,10,22 all analyses were also stratified by race/ethnicity.
Regression-Derived Approach
The goal of the regression-derived approach was to identify the home BP levels that corresponded to specific clinic BP levels. 19, 20, 23, 24 Using the intercept and β-coefficient from a Deming regression model with home SBP as the dependent and clinic SBP as the independent variable, the level of home SBP and 95% CI corresponding to clinic SBP level of 140 mm Hg were estimated. Home SBP levels corresponding to clinic SBP of 120, 130, and 160 mm Hg were also determined. We used the same approach to determine home DBP levels corresponding with clinic DBP of 80, 85, and 100 mm Hg. Comparisons of home BP thresholds at each level of clinic SBP and DBP among blacks, whites, and Hispanics were performed using unpaired t test. The 0.01 level of significance was used for multiple testing. To determine whether the order of home versus clinic visit may influence home BP estimates, we performed additional Deming regression analysis in the NCMH cohort in which home BP between the second and third clinic visits was used as the dependent and the third clinic visit BP as the independent variable (home before clinic BP measurement), as well as analysis using home BP between fourth to fifth clinic visit as the dependent and the fourth clinic visit BP as independent (clinic before home BP measurement). December 2018
Outcome-Derived Approach
The goal of the outcome-derived approach was to identify the threshold for home BP that corresponded to the same probability of an event associated with a clinic BP level (eg, SBP of ≥130 mm Hg). 21, 25 Higher clinic SBP was associated with the composite of cardiovascular events or all-cause mortality (P<0.001) but clinic DBP was not (P=0.215). Therefore, thresholds for home SBP but not DBP were calculated. Thresholds for home SBP yielding similar 5-year predicted probability of the composite outcome associated with clinic SBP ≥130 mm Hg were first calculated. To do this, we performed Cox regression with the composite outcome of all-cause mortality or cardiovascular disease (CVD; unstable angina, myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention, stroke, transient ischemic attack, cerebrovascular revascularization, peripheral artery revascularization, hospitalization for atrial fibrillation, or heart failure) and clinic SBP as the independent variable in the primary analysis. In the secondary analysis, only coronary heart disease, stroke, and heart failure are considered as outcomes. We identified the 5-year predicted probability of CVD or mortality for a clinic BP level of 130 mm Hg. Next, we developed a Cox regression model with the composite outcome of all-cause mortality/CVD and home SBP as the independent variable. From this latter model, we determined the home SBP value that corresponded to the 5-year predicted probability of the outcome for a clinic SBP level. A bootstrap with 1000 data sets was used to calculate a 95% CI for the home SBP yielding a similar 5-year predicted probability of the composite cardiovascular events/all-cause mortality outcome. Home SBP levels yielding similar 5-year predicted probability of an outcome associated with clinic SBP ≥120, ≥130, ≥140, and ≥160 mm Hg were also calculated.
Results
Baseline characteristics of participants in DHS and NCMH cohorts are shown in Table 1 . Participants taking antihypertensive medication in the DHS cohorts were older and more likely to be black, women, and to have concomitant chronic kidney disease or diabetes mellitus compared with those not taking antihypertensive medication. Additionally, mean body mass index was higher among those taking versus not taking antihypertensive medication. Clinic and home BP were each higher among participants taking versus not taking antihypertensive medication, whereas no differences were present for heart rate. The DHS participants consisted of 757 untreated whites, 164 treated whites, 1080 untreated blacks, 412 treated blacks, 447 untreated Hispanics, and 56 treated Hispanics. The NCMH participants consisted of 305 untreated whites, 84 untreated blacks, and only 14 untreated Hispanics. Baseline characteristics of blacks, whites, and Hispanics in the DHS are shown in Table S1 in the onlineonly Data Supplement. Because the number of Hispanics in the NCMH is small, home BP analysis was not performed in this subgroup.
Regression-Derived Approach to Determine Home BP Thresholds in DHS and NCMH
Among participants not taking antihypertensive medication in DHS, the regression-derived thresholds for home BP corresponding to clinic BP for stage 1 hypertension were similar between blacks and whites (129/80 versus 130/80 mm Hg, respectively; Table 2 ). Home BP corresponding to clinic BP for stage 2 hypertension in DHS (clinic BP of 140/90 mm Hg) was also similar between blacks and whites (134/83 versus 137/88 mm Hg, respectively; Table 2 ). Home SBP thresholds for stage 1 and 2 hypertension, however, were significantly lower in untreated Hispanics when compared with untreated blacks and whites (126 and 130 mm Hg, respectively; both P<0.001 versus blacks and whites; Table 2 ; Figures 1 and 2) , whereas DBP thresholds were not (all P >0.1 versus blacks and whites). These ethnic differences in home SBP thresholds were not observed among treated participants (Table 3 ). In the NCMH cohort, the regression-derived thresholds for home BP corresponding to clinic BP for stage 1 and stage 2 hypertension were 131/82 and 138/90 mm Hg in untreated blacks and 130/79 and 139/87 mm Hg in whites, respectively, which are similar to thresholds in the untreated DHS black and white groups ( Table 2 ). In analyses modifying the number of home BP measurements included, the thresholds remained unchanged (Tables 2 and 3 ). Home SBP/DBP thresholds correlating with clinic BPs of 120/80, 130/85, and 160/100 mm Hg among participants not taking antihypertensive medication are also shown in Table 2 and Figure 1 . Home SBP and DBP thresholds corresponding to the same clinic SBP/DBP cutoff were generally higher among participants taking versus not taking antihypertensive medication (Table 3) .
Because home visit occurred before clinic visit in DHS, additional regression analysis in the NCMH cohort was performed by comparing home BP thresholds using home BP between the second and third clinic visits as the dependent and BP from the third clinic visit as the independent variable (home before clinic BP measurement) to the thresholds derived from home BP measured between the fourth to fifth clinic visits against clinic BP from the fourth clinic visit (clinic before home BP measurement; Table S2 ). The results remain similar, suggesting minimal regression to the mean during multiple visits.
Outcome-Derived Approach to Determine Home BP Thresholds in DHS
Because cardiovascular outcome data were not available in the NCMH cohort, analysis was conducted only in the DHS cohort. During a median follow-up of 11 years (25th-75th percentile of 10.5-11.6 years), there were 341 first composite CVD events and all-cause mortality events.
Composite CVD events and all-cause mortality events were higher at increasing levels of clinic SBP and higher in blacks than in whites and Hispanics ( (Table 4) . When the outcomes were restricted only to coronary heart disease, stroke, and heart failure, the home SBP thresholds for stage 1 and stage 2 hypertension derived from more restricted outcomes remain similar to the original analysis using composite outcomes and allcause mortality (Table S3) .
Discussion
In both primary care clinic cohort and a population-based sample of Dallas county residents, we determined home BP thresholds, which correspond to stage 1 and 2 hypertension according to the new ACC/AHA guidelines, using 2 independent approaches. We have identified a similar home BP threshold corresponding to stage 1 hypertension proposed by the guidelines by both a regression approach and an outcome approach in treated and untreated blacks, whites, and Hispanics, which has implications in both diagnosis and treatment of hypertension. Furthermore, these results are consistent and reproducible even when all or fewer readings of home BP measurements are considered in the analysis. Previous studies have determined diagnostic thresholds for home BP based on outcome-based approaches. 7 These home BP thresholds were found to be generally lower than clinic BP thresholds for diagnosis of hypertension. However, these BP cutoffs were derived from populations from Japan, Finland, Greece, and Uruguay. 7 None of the data were derived from population-based studies conducted in the United States. Furthermore, BP thresholds for diagnosis of hypertension have been reduced from 140/90 mm Hg used in these studies to 130/80 mm Hg by the current ACC/AHA high BP guidelines. A recent analysis from the JHS demonstrated that daytime BP threshold assessed by 24-hour ambulatory BP monitoring is higher than the published recommendation, which is also derived from non-US populations. 9 Because JHS was conducted only in blacks, the impact of race/ethnicity on out-of-office BP cannot be evaluated. In another recent study conducted mainly in a university-employed middle-aged white population in New York, the investigators also reported higher awake/ daytime ambulatory BP than clinic BP. 12 The inconsistency of thresholds reported from international studies versus US studies may be because of differences in the prevalence of masked hypertension among populations. When we used the regression approach, we found that our home BP thresholds for blacks and whites generally corre- thresholds are significantly lower for untreated Hispanics than other ethnic/racial groups. When we used the outcome approach, however, the home SBP thresholds are consistent with the guidelines for stage 1 hypertension, ranging from 130 to 134 mm Hg in all ethnic/racial groups regardless of hypertension treatment status. Because the outcome approach is considered to be the gold standard approach, our data provide support for the home BP thresholds proposed by the new ACC/AHA guidelines. Because the clinic BP threshold of 130/80 mm Hg is also proposed by the ACC/AHA guidelines as the target BP for treatment in the office, our study results suggested that home BP of 130/80 mm Hg can be used as home BP target for treatment in most hypertensive patients.
By the outcomes approach, home SBP of 140 mm Hg in untreated blacks and 142 to 143 mm Hg in untreated Hispanics corresponding to stage 2 hypertension was slightly higher than levels in untreated whites (135-136 mm Hg) and the guideline-recommended thresholds of 135 mm Hg by the outcome approach. Our findings in a multiethnic cohort are consistent with JHS, which demonstrated that the mean daytime SBP that corresponded with a clinic SBP of 140 mm Hg was also 140 mm Hg. 9 Although the outcome approach is considered to be a gold standard in establishing a normal range of home BP and ambulatory BP in a given population, it is unclear how BP thresholds should be determined when cardiovascular outcomes are different among populations. This is particularly important in blacks-the population with the highest susceptibility to hypertension-related cardiovascular injury, 26 stroke, 27 and overall mortality. 28 In a recent population-based longitudinal cohort study, each increase in SBP by 10 mm Hg was associated with a 24% increase in risk of stroke in blacks compared with 8% in whites. 27 Nevertheless, the difference between the guideline-recommended home BP threshold for stage 2 hypertension and our outcome-derived home SBP threshold is modest (135 versus 140 mm Hg) and is likely to impact a small proportion of the population. In the DHS cohort, only 4.2% of blacks and 3.1% of nonblacks were found to have home SBP between 135 and 140 mm Hg and home DBP <80 mm Hg.
Our study is limited to young and middle-aged adults because we excluded persons >65 years of age. The majority of our subjects were overweight or obese, and results may not be applicable to normal weight or lean subjects. Participants included in the analysis are limited to Dallas-Fort Worth, TX and Durham, NC. The study results may not be applicable to other geographic regions in the United States. Nevertheless, our data represent the first population-based study in the United States that determined home BP thresholds that correspond to each clinic BP cutoff, using a standardized protocol. Home BP measurement was obtained by surveyors in the DHS, which may yield higher values than self-BP measurement. However, we think that differences are likely to be minimal as the use of nonmedical ethnically congruent field staff members in the DHS should have minimized the alerting reaction during home BP measurement.
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Furthermore, home BP thresholds derived from DHS in the regression-based approach were largely identical to home BP thresholds from the NCMH study, which used ≤60 self-BP measurements in the absence of surveyors during multiple consecutive days. Our data suggested that the impact of an observer during home BP measurement is minimal if an automatic oscillometric device is used to measure BP.
Perspectives
Home BP measurement has the advantage over ambulatory BP monitoring because it is more practical, widely available for clinical use, and of lower cost. It was estimated that between 30% and 45% of hypertensive US adults engage in home BP monitoring at least on a monthly basis. 29 Our data based on 2 independent cohorts provide support for the use of home BP threshold of 130/80 mm Hg for diagnosis of hypertension as proposed by the 2017 ACC/AHA high BP guideline in blacks, whites, and Hispanics, which should inform clinicians in the diagnosis and treatment of hypertension in a large number of hypertensive patients who regularly monitor their home BP. 
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